Zyla Life Sciences Finite-Lived Intangible Asset, Expected Amortization, Year Four
Zyla Life Sciences had Finite-Lived Intangible Asset, Expected Amortization, Year Four of $13.56 million as of 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour · last filed 2020-03-26
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $13.56M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $26.00K.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $1.14M.
- 2016-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Four $1.10M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Four |
|---|---|
| 2019-12-31 | $13.56M 10-K · filed 2020-03-26 |
| 2018-12-31 | $26.00K 10-K · filed 2019-03-29 |
| 2017-12-31 | $1.14M 10-K · filed 2018-03-16 |
| 2016-12-31 | $1.10M 10-K · filed 2017-03-13 |
| 2015-12-31 | $2.00M 10-K · filed 2016-03-11 |